• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Endotypes of Severe Asthma: 5 Questions on Pathways, Biomarkers, Biologics

Slideshow

Key factors in choosing appropriate biologic therapy for a patient with severe asthma include consideration of the specific mechanistic pathway that underlies the presentation, investigation of biomarker levels, and evaluation of comorbid inflammatory disease.

Following are 5 questions on these topics that are based on a comprehensive review and international expert opinion published in the Journal of Allergy and Clinical Immunology: In Practice by a group of clinicians recognized internationally for knowledge of severe asthma and of biologic medications. Test your endotype IQ.

Related Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate

Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate

Grace Halsey
February 7th 2025
Article

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Fall Risk Near End of Life in COPD / image credit ©Toa555/shutterstock.com

5 Drug Classes Linked to Increased Fall Risk Among Adults with COPD Near End of Life

Grace Halsey
January 30th 2025
Article
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Mediar Therapeutics and Lilly Enter Global Licensing Agreement for WISP1 Antibody in Idiopathic Pulmonary Fibrosis

Mediar Therapeutics and Lilly Enter Global Licensing Agreement for WISP1 Antibody in Idiopathic Pulmonary Fibrosis

Patient Care Staff
January 13th 2025
Article

The planned Phase 2 trial in IPF will focus on assessing MTX-463’s safety, pharmacokinetics, and efficacy.

FDA Updates RSV Vaccine Labels to Include Guillain-Barré Syndrome Warning / Image credit: ©MargJohnsonVA/AdobeStock

FDA Updates RSV Vaccine Labels to Include Guillain-Barré Syndrome Warning

Sydney Jennings
January 8th 2025
Article

The FDA approved the addition of Guillain-Barré syndrome warnings for Abrysvo and Arexvy, citing postmarketing data suggesting an increased risk.

© 2025 MJH Life Sciences

All rights reserved.